SanBio Co (TSE:4592) Debt-to-Equity : 0.24 (As of Jan. 2024)

View and export this data going back to 2015. Start your Free Trial

What is SanBio Co Debt-to-Equity?

SanBio Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was 円268.00 Mil. SanBio Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was 円397.00 Mil. SanBio Co's Total Stockholders Equity for the quarter that ended in Jan. 2024 was 円2,792.40 Mil. SanBio Co's debt to equity for the quarter that ended in Jan. 2024 was 0.24.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for SanBio Co's Debt-to-Equity or its related term are showing as below:

TSE:4592' s Debt-to-Equity Range Over the Past 10 Years
Min: -13.75 Med: 0.32 Max: 2.7
Current: 0.24

During the past 11 years, the highest Debt-to-Equity Ratio of SanBio Co was 2.70. The lowest was -13.75. And the median was 0.32.

TSE:4592's Debt-to-Equity is ranked worse than
59.67% of 1081 companies
in the Biotechnology industry
Industry Median: 0.15 vs TSE:4592: 0.24

SanBio Co Debt-to-Equity Historical Data

The historical data trend for SanBio Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SanBio Co Debt-to-Equity Chart

SanBio Co Annual Data

Trend

Jan15

Jan16

Jan17

Jan18

Jan19

Jan20

Jan21

Jan22

Jan23

Jan24

Debt-to-Equity

Get a 7-Day Free Trial

0.37

0.48

1.24

0.21

0.24

SanBio Co Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Debt-to-Equity	Get a 7-Day Free Trial															0.21	0.23	0.36	0.39	0.24

Competitive Comparison of SanBio Co's Debt-to-Equity

For the Biotechnology subindustry, SanBio Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SanBio Co's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SanBio Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where SanBio Co's Debt-to-Equity falls into.

SanBio Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

SanBio Co's Debt to Equity Ratio for the fiscal year that ended in Jan. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(268	+	397)	/	2792.398
	=	0.24

SanBio Co's Debt to Equity Ratio for the quarter that ended in Jan. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(268	+	397)	/	2792.398
	=	0.24

SanBio Co (TSE:4592) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

SanBio Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of SanBio Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

SanBio Co (TSE:4592) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SanBio Co Ltd (TSE:4592) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

SNBIF:USA

Address

8-1 Street Luke Tower 32nd Floor, Akashi-cho, Chuo-ku, Tokyo, JPN, 104-0044

Website

https://www.sanbio.com

SanBio Co Ltd is engaged in the research and development of regenerative cells drugs. The company has three types of drugs under development, including nerve regeneration cell SB623, used for the treatment of chronic cerebral infarction, traumatic brain injury, age-related macular degeneration, retinitis pigmentosa, Parkinson's disease, spinal cord injury and Alzheimer's disease; enhanced type-mesenchymal stem cells SB618, used to treat peripheral neuropathy, as well as muscle stem cells SB308, used in the treatment of muscular dystrophy.

SanBio Co (TSE:4592) Headlines

No Headlines